Group 1 - Spyre Therapeutics is a clinical-stage biotechnology company focused on developing advanced treatments for Inflammatory Bowel Disease (IBD) and other immune-mediated diseases through innovative antibody engineering and therapeutic combinations [1][2] - The company will participate in two upcoming investor conferences: Jefferies Global Healthcare Conference on June 4, 2025, and Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025 [1] - Live audio webcasts and replays of the investor events will be accessible on Spyre's investor events website [1] Group 2 - Spyre's product pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23, indicating a strong focus on next-generation therapies for IBD and immune-mediated diseases [2] - The company emphasizes a combination of best-in-class antibody engineering and dose optimization in its research and development efforts [2]
Spyre Therapeutics to Participate in Upcoming June Investor Conferences